Rankings / Hormones & Endocrine
Enclomiphene citrate
Hormones & Endocrine · SERM (HPG restart)
Tier B-
Bottom line
Read Off Label grades Enclomiphene citrate as B- (6.3/10) based on moderate evidence, med benefit magnitude, and a low-med-risk safety profile.
Cleaner pharmacology than mixed clomiphene because it lacks zuclomiphene, the longer-lived estrogenic isomer.
Studied, labeled, or reported-use context: 12. — Investigational / compounded; not individualized guidance.
Citation correction in progress
2 PubMed links were found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Cleaner pharmacology than mixed clomiphene because it lacks zuclomiphene, the longer-lived estrogenic isomer. Phase 2/3 studies showed testosterone restoration while maintaining sperm counts, unlike testosterone gel. FDA did not approve Androxal after the 2015 review cycle, so US access is compounded or research-market rather than an approved product. Hohl 2025 grouped clomiphene and enclomiphene SERMs and found higher TT, LH, and FSH versus placebo; That finding does not establish identical risk.
Mechanism
Trans isomer of clomiphene; estrogen receptor antagonist at hypothalamus/pituitary; raises GnRH → LH/FSH → endogenous testosterone while preserving spermatogenesis in secondary hypogonadism
Studied, labeled, or reported dose & route
12.5-25 mg/day PO in trials and common compounded protocols
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Enclomiphene citrate's effects?
- Read Off Label rates the evidence for Enclomiphene citrate as Moderate and the benefit magnitude as med, producing an overall grade of B- (6.3/10). Cleaner pharmacology than mixed clomiphene because it lacks zuclomiphene, the longer-lived estrogenic isomer.
- What safety findings are reported for Enclomiphene citrate?
- Enclomiphene citrate has a low-med risk profile in the database. Low-Med (appears cleaner than mixed clomiphene in trials; limited long-term and post-market safety; compounded-product quality risk) Legal status: Investigational / compounded (Androxal was not FDA-approved; no FDA-approved US product).
- What doses or routes are reported for Enclomiphene citrate?
- 12.5-25 mg/day PO in trials and common compounded protocols This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Enclomiphene citrate work?
- Trans isomer of clomiphene; estrogen receptor antagonist at hypothalamus/pituitary; raises GnRH → LH/FSH → endogenous testosterone while preserving spermatogenesis in secondary hypogonadism
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.